XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Collaborative Arrangements (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2024
Collaborative Arrangements [Abstract] |
Collaboration Arrangements | Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31, |  |
($ in millions) | 2024 |  | 2023 |  |  |  |
Alliance revenue - Lynparza | $ | 292 |  |  | $ | 275 |  |  |  |  |
Alliance revenue - Koselugo | 38 |  |  | 23 |  |  |  |  |
Total alliance revenue | $ | 330 |  |  | $ | 298 |  |  |  |  |
Cost of sales (1) | 82 |  |  | 70 |  |  |  |  |
Selling, general and administrative | 39 |  |  | 47 |  |  |  |  |
Research and development | 20 |  |  | 21 |  |  |  |  |
($ in millions) | March 31, 2024 |  | December 31, 2023 |  |  |  |
Receivables from AstraZeneca included in Other current assets | $ | 334 |  |  | $ | 341 |  |  |  |  |
Payables to AstraZeneca included in Accrued and other current liabilities (2) | 617 |  |  | 256 |  |  |  |  |
Payables to AstraZeneca included in Other Noncurrent Liabilities (2) | — |  |  | 600 |  |  |  |  |
(1) Represents amortization of capitalized milestone payments. (2) Includes accrued milestone payments. Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31, |  |
($ in millions) | 2024 |  | 2023 |  |  |  |
Alliance revenue - Lenvima | $ | 255 |  |  | $ | 232 |  |  |  |  |
Cost of sales (1) | 60 |  |  | 126 |  |  |  |  |
Selling, general and administrative | 39 |  |  | 51 |  |  |  |  |
Research and development | 8 |  |  | 39 |  |  |  |  |
($ in millions) | March 31, 2024 |  | December 31, 2023 |  |  |  |
Receivables from Eisai included in Other current assets | $ | 255 |  |  | $ | 226 |  |  |  |  |
Payables to Eisai included in Accrued and other current liabilities (2) | 125 |  |  | 125 |  |  |  |  |
(1) Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above. (2) Represents an accrued milestone payment. Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31, |  |
($ in millions) | 2024 |  | 2023 |  |  |  |
Alliance revenue - Adempas/Verquvo | $ | 98 |  |  | $ | 99 |  |  |  |  |
Net sales of Adempas recorded by Merck | 70 |  |  | 59 |  |  |  |  |
Net sales of Verquvo recorded by Merck | 5 |  |  | 7 |  |  |  |  |
Total sales | $ | 173 |  |  | $ | 165 |  |  |  |  |
Cost of sales (1) | 62 |  |  | 57 |  |  |  |  |
Selling, general and administrative | 33 |  |  | 33 |  |  |  |  |
Research and development | 28 |  |  | 25 |  |  |  |  |
($ in millions) | March 31, 2024 |  | December 31, 2023 |  |  |  |
Receivables from Bayer included in Other current assets | $ | 155 |  |  | $ | 156 |  |  |  |  |
Payables to Bayer included in Accrued and other current liabilities | 74 |  |  | 80 |  |  |  |  |
(1) Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories. Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31, |  |
($ in millions) | 2024 |  | 2023 |  |  |  |
Net sales of Lagevrio recorded by Merck | $ | 350 |  |  | $ | 392 |  |  |  |  |
Cost of sales (1) | 191 |  |  | 221 |  |  |  |  |
Selling, general and administrative | 16 |  |  | 27 |  |  |  |  |
Research and development | (5) |  |  | 16 |  |  |  |  |
($ in millions) | March 31, 2024 |  | December 31, 2023 |  |  |  |
Payables to Ridgeback included in Accrued and other current liabilities (2) | $ | 160 |  |  | $ | 113 |  |  |  |  |
(1) Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves. (2) Includes accrued royalties. Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31, |  |
($ in millions) | 2024 |  | 2023 |  |  |  |
Selling, general and administrative | $ | 3 |  |  | $ | — |  |  |  |  |
Research and development | 69 |  |  | — |  |  |  |  |
($ in millions) | March 31, 2024 |  | December 31, 2023 |  |  |  |
Payables to Daiichi Sankyo included in Accrued and other current liabilities | $ | 817 |  |  | $ | 800 |  |  |  |  |
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities | 750 |  |  | 750 |  |  |  |  |
Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31, |  |
($ in millions) | 2024 |  | 2023 |  |  |  |
Selling, general and administrative | $ | 2 |  |  | $ | 1 |  |  |  |  |
Research and development | 69 |  |  | 26 |  |  |  |  |
($ in millions) | March 31, 2024 |  | December 31, 2023 |  |  |  |
Payables to Moderna included in Accrued and other current liabilities | $ | 72 |  |  | $ | 63 |  |  |  |  |

X
- Definition Collaborative Arrangements [Abstract] + References No definition available. + Details
Name: | mrk_CollaborativeArrangementsAbstract
Namespace Prefix: | mrk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration